Dermatitis atopic

26 trials 8 recruiting MedDRA PT
26 Registered trials
8 Recruiting
11 Unique sponsors
15 Unique IMPs
26 Commercial trials
Drug classes (ATC)
— ATC code not specified 25
D Dermatology (ATC D) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Monoclonal antibody 2 substances
Monoclonal antibody (immune) 1 substance
JAK inhibitor 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 9 Phase II/III: 1 Phase II: 13 Phase III/IV: 1 Phase I: 2 Phase I (Other): 1

Filter these 26 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 26 trials

Phase III

9 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2022-502936-38-00 15 countries 2019 n=380
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2022-502937-24-00 18 countries 2019 n=444
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2022-502938-30-00 9 countries 2018 n=187
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-504713-76-00 12 countries 2024 n=260
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2022-501196-41-00 4 countries 2024 n=147
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2023-506558-20-00 6 countries 2024 n=216
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2023-508096-36-00 11 countries 2024 n=287
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2023-508099-12-00 7 countries 2024 n=90
    Recruiting
  • Sanofi-Aventis Research & Development Commercial
    AMLITELIMAB
    2023-506557-38-00 7 countries 2024 n=188
    Ended

Phase II/III

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    AMLITELIMAB
    2023-506548-18-00 13 countries 2022 n=457
    Recruiting

Phase II

13 trials
  • Aslan Pharmaceuticals Pte Ltd Commercial
    EBLASAKIMAB
    2023-508329-28-00 2 countries n=50
    Pending
  • Bioprojet Pharma Commercial
    BP1.7881A
    2022-502045-10-00 3 countries 2023 n=81
    Ended
  • Galderma S.A. Commercial
    NEMOLIZUMAB
    2024-514405-65-00 3 countries 2021 n=100
    Ended
  • Galenica AB Commercial
    PROPYLENE GLYCOL; PROPYLENE GLYCOL, UREA
    2025-521620-29-01 2 countries 2026 n=78
    Recruiting
  • Janssen - Cilag International Commercial
    DUPILUMAB; NM26-2198
    2024-517814-13-00 3 countries 2025 n=86
    Ended
  • Janssen - Cilag International Commercial
    JNJ-95597528
    2025-523464-20-00 2 countries 2026 n=14
    Recruiting
  • Nektar Therapeutics Commercial
    REZPEGALDESLEUKIN
    2023-507456-69-00 7 countries 2024 n=366
    Ended
  • Novartis Pharma AG Commercial
    GHZ339
    2024-519081-49-00 9 countries 2025 n=104
    Recruiting
  • Novartis Pharma AG Commercial
    GIA632
    2025-521503-43-00 5 countries 2026 n=52 Orphan
    Halted
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR444656
    2023-504346-66-00 4 countries 2024 n=180
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    LUNSEKIMIG
    2024-511549-20-00 2 countries 2025 n=108
    Ended
  • Sanofi-Aventis Research & Development Commercial
    AMLITELIMAB
    2022-502188-39-00 8 countries 2023 n=357
    Ended
  • Bioprojet Pharma Academic
    BP1.7881A
    2022-502045-10-00 3 countries 2023 n=81
    Ended

Phase III/IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-504869-23-00 10 countries 2023 n=272
    Ended

Phase I

2 trials
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2025-523826-41-00 1 country 2026 n=207
    Recruiting
  • Sitryx Therapeutics Limited Commercial
    IMP not specified
    2025-522216-17-00 4 countries 2026 n=28
    Recruiting

Phase I (Other)

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2024-513495-17-00 2 countries 2024 n=30
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 9 Phase I, Phase II/III, Phase I (Other), Phase II, Phase III 3
AbbVie Deutschland GmbH & Co. KG Commercial 5 Phase III/IV, Phase III 1
Bioprojet Pharma Commercial 2 Phase II 0
Janssen - Cilag International Commercial 2 Phase II 1
Novartis Pharma AG Commercial 2 Phase II 1
Sanofi-Aventis Research & Development Commercial 2 Phase II, Phase III 0
Sitryx Therapeutics Limited Commercial 1 Phase I 1
Aslan Pharmaceuticals Pte Ltd Commercial 1 Phase II 0
Galderma S.A. Commercial 1 Phase II 0
Galenica AB Commercial 1 Phase II 1
Nektar Therapeutics Commercial 1 Phase II 0
New trials by year
2019
2
2021
1
2022
1
2023
4
2024
9
2025
3
2026
5
← All indication landscapes